U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07422805) titled 'Circulating Tumor DNA in Melanoma Patients' on Feb. 05.
Brief Summary: The aim of this prospective observational study is to determine whether the presence and quantity of circulating tumor DNA (ctDNA) can serve as a predictive factor for recurrence or progression of melanoma. The study will evaluate the association between ctDNA detection and quantification and relevant clinical and histopathological prognostic parameters. The goal is to assess whether ctDNA may be useful as a biomarker for monitoring disease course and predicting outcomes in melanoma patients.
Study Start Date: Nov. 01, 2021
Study Type: INTERVENTIONAL
Condition...